In both clinical cases, namely, GLA (Patient 1) and generalized lymphadenopathy (Patient 2), mutations in the PI3K/Akt/mTOR pathway were observed; hence, the administration of SIR (mTOR inhibitor) to treat such conditions is justified, which has led to increased interest in its use as a part of polytherapy for these disorders [7,35]. The gene discussed is MTOR; the disease is diffuse lymphatic malformation.